


GE Healthcare JP Morgan Conference

Pascale Witz

President & CEO, Medical Diagnostics

January 10, 2012



imagination at work

Caution Concerning Forward-Looking Statements:

This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: current economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets; potential market disruptions or other impacts arising in the United States or Europe from developments in the European sovereign debt situation; the impact of conditions in the financial and credit markets on the availability and cost of General Electric Capital Corporation’s (GECC) funding and on our ability to reduce GECC’s asset levels as planned; the impact of conditions in the housing market and unemployment rates on the level of commercial and consumer credit defaults; changes in Japanese consumer behavior that may affect our estimates of liability for excess interest refund claims (Grey Zone); potential financial implications from the Japanese natural disaster; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; the adequacy of our cash flow and earnings and other conditions which may affect our ability to pay our quarterly dividend at the planned level; our ability to convert customer wins (which represent pre-order commitments) into orders; the level of demand and financial performance of the major industries we serve, including, without limitation, air and rail transportation, energy generation, real estate and healthcare; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of financial services regulation; strategic actions, including acquisitions, joint ventures and dispositions and our success in completing announced transactions and integrating acquired businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

“This document may also contain non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures presented in this document, see the accompanying supplemental information posted to the investor relations section of our website at www.ge.com.”


“Effective January 1, 2011, we reorganized our segments. We have reclassified prior-period amounts to conform to the current-period’s presentation.”

“In this document, “GE” refers to the Industrial businesses of the Company including GECS on an equity basis. “GE (ex. GECS)” and/or “Industrial” refer to GE excluding Financial Services.”

\$17B broad technology portfolio

Diagnostic & Clinical Equipment

~46% of revenue



Diagnostic imaging



Clinical products



Home health

\$7.8B

Information Tech. and Services

~34% of revenues



Electronic medical records (EMR)



Picture Archiving System (PACS)



Clinical knowledge solutions



Equipment service solutions


\$5.7B

Molecular Medicine

~20% of revenues




Bio-process



Protein & cell sciences




Contrast media



Molecular diagnostics

\$3.3B

A global business model ... 53% revenue non-U.S.



Global growth drivers

- High-tech infrastructure spending
- Low protectionism
- Large regional competitors
- Low manufacturing capital investment
- Globally translatable technology

Industry characteristics

- High technology and IP
- Highly regulated
- Domain expertise required


Demographic trends escalating demand

Populations aging

- 2030: the number of people over 65 will
 - Increase 140% in developing world
 - Increase 51% in developed world
- 48.6% relative lifetime healthcare expenditure is expended after age 65


...and demand is growing

- Global number of Alzheimer's patients will grow from 36 million in 2009 to 66 million in 2030 and 115 million in 2050
- Global number of cancer patients is predicted to grow from 10.1 million in 2000 to 15.7 million in 2020
- US: chronic disease up 80% and spending up 260% over last 20 years. Spend to increase 2.5X by 2023







GE strategy addresses macro trends in healthcare

GE Delivering




FDA-valid genomic biomarkers in drug labels



OmnyxTM

A GE Healthcare and UPMC Venture

GEHC- Enables Personalized Medicine



Radiology & pathology - enablers of personalized medicine

Early detection

Complete patient diagnostics

Personalized therapy

GP



Radiologist

Pathologist

Oncologist



Image-guided biopsies



Screening

Imaging

Biopsy analysis


Treatment decision and monitoring

Suspicion of cancer, more tests needed
Radiology imaging for mass confirmation, location
Therapy selection limited

Definitive diagnostic... tissue-based today
Advanced radiology... activity, molecular
Enables specific therapy selection

GE supports increased needs in pathology

Assets and capabilities positioned to answer trends in personalized medicine



Clariant: pathology tests services

Entry to the market via services

Clariant acquired Dec 2010

~ 450 employees, 300 tests for Cancer Diagnostics

Great reputation, customer base of >2,000 pathologists in the US


Ongoing globalization using GEHC infrastructure

Introduction of proprietary innovative technology for pathology


Genetic
fingerprint




Genetic messages



Protein expression



Cell function



Digital Pathology



High throughput with slide digitization

From glass

... to digital



A GE Healthcare and UPMC Venture




Digitalization improves capacity; enables quick and accurate share of information

Oncology PET Imaging ...

.... Meeting clear unmet medical need

Tumor detection

Detection of metastatic prostate cancer



Therapy monitoring

Monitoring efficacy of anti-angiogenic therapy

Test to measure response of tumors to anti-angiogenic therapy



Scan




Treat
(2 wks)



Scan




Analyse & report



GE innovations will create new insights


GE research center advances pathology

From 1 test/slice




...to 50+ tests/slice

With multiplexing capability




Groundbreaking technology in Pathology

GE continues to lead the integration of diagnostic solutions




Better companion diagnostics needed for Rx development



Alzheimer's Disease ...


... an unmet need for complete Dx solution



Enabling First Generation of Disease Modifying Drugs

The imaging agents described are not approved for use by the FDA or any other health regulatory agency


Medical Diagnostics - Broad range of technologies with prominent global presence



Leader in
in-vivo imaging



Clarient –
molecular Dx &
Pharma R&D
hub




Proprietary
technology for
R&D and clinical
use



Innovative
digital solutions
for pharma and
clinical labs

>53,000 GEHC employees with WW infrastructure

GE – driving personalized medicine



1. Be a global diagnostics leader, supporting Personalized Medicine growth
2. Be pharma's partner of choice in personalized medicine
3. Invest in new platforms – stream line the radiology – pathology diagnostic workflow
4. Investing in pathology... to be a leader in companion diagnostics and pathology frontiers
5. Leading the way in healthcare digitalization

Thank you